<DOC>
	<DOCNO>NCT01104701</DOCNO>
	<brief_summary>The purpose Study BCB111 collect efficacy , pharmacokinetic , pharmacodynamic , safety , tolerability data patient type 2 diabetes assess feasibility monthly dose exenatide suspension formulation .</brief_summary>
	<brief_title>A Study Examine Efficacy , Safety Tolerability , Pharmacokinetics Exenatide Once Monthly Suspension</brief_title>
	<detailed_description />
	<mesh_term>Exenatide</mesh_term>
	<criteria>Is least 18 year old study start Has diagnose type 2 diabetes mellitus Has HbA1c 7.1 % 11.0 % , inclusive , study start Has treat diet exercise alone stable regimen metformin , pioglitazone , combination metformin pioglitazone , minimum 2 month prior study start Either treat stable treatment regimen follow medication minimum 2 month prior study start : hormone replacement therapy ( female subject ) ; antihypertensive agent ; thyroid replacement therapy ; antidepressant agent Clinically significant medical condition could potentially affect study participation include : Acute chronic pancreatitis Personal family history medullary thyroid carcinoma multiple endocrine neoplasia ( MEN ) type 2 Active cardiovascular disease within 3 month study start Underlying hepatic renal disease Inflammatory bowel disease , severe gastrointestinal disease ( particularly may affect gastric emptying , gastroparesis , pyloric stenosis , metabolic surgery ) Has &gt; 2 episode major hypoglycemia precede 6 month study start Has receive investigational drug within 30 day ( 5 halflives investigational drug , whichever great ) prior study start Has treat , currently treat , expect require undergo treatment follow treatment exclude medication : Any exposure exenatide ( BYETTA® , exenatide weekly , exenatide suspension ) , liraglutide ( Victoza® ) , GLP1 receptor agonist Any DPPIV inhibitor , sulfonylurea ( SU ) , rosiglitazone ( Avandia® ) within 3 month prior study start Alpha glucosidase inhibitor , meglitinide , nateglinide , pramlintide ( SYMLIN® ) within 30 day prior study start Insulin within 2 week prior study start , 1 week within 3 month prior study start Systemic corticosteroid oral , intravenous , intraarticular , intramuscular route ; potent , inhale , intrapulmonary ( include ADVAIR® ) steroid know high rate systemic absorption Prescription overthecounter weight loss medication within 3 month prior study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Exenatide</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
	<keyword>Byetta</keyword>
	<keyword>Exenatide Once Weekly</keyword>
</DOC>